68Ga-DOTATATE Imaging in Neuroendocrine Tumors
| Registry | NCT02174679 |
|---|---|
| Status | No longer available |
| Study type | Expanded access |
| Sponsor | Jonsson Comprehensive Cancer Center (Other) |
| Conditions | Carcinoid Cancer, Neuroendocrine Tumors, Medullary Thyroid Cancer, Cancers Expressing Somatostatin Receptors |
| Interventions | 68Ga DOTATATE (Drug) |
| Dates | first posted 2014-06-25, last updated 2020-07-27 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Carcinoid Cancer All trials for Neuroendocrine Tumors All trials of 68Ga DOTATATE
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Older than 18 years the time of radiotracer administration * Provides written informed consent * Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline * Able to remain still for duration of each imaging procedure (about 30 minutes) Exclusion Criteria: * Less than 18 years-old at the time of radiotracer administration * Pregnant or nursing * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
| Facility | City | Country | Status |
|---|---|---|---|
| UCLA Hospital | Los Angeles, California | United States |